Rx/Reimbursement Adult Incontinence in Belgium - Product Image

Rx/Reimbursement Adult Incontinence in Belgium

  • ID: 4538310
  • Report
  • Region: Belgium
  • 13 pages
  • Euromonitor International
1 of 4
Belgian people suffering from incurable incontinence can benefit from an allocation from the government. The patient must go to the general practitioner who, if recognising the problem as an incurable disease, fills in a form to attest to the incontinence. The patient then has to take this form to the health fund he/she is affiliated to and will receive an allocation of EUR162.3 per year.

The Rx/Reimbursement adult incontinence in Belgium report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2013-2017, allowing you to identify the sectors driving growth. It identifies the leading companies, the leading brands and offers strategic analysis of key factors influencing the market – be they new product developments, distribution or pricing issues. Forecasts to 2022 illustrate how the market is set to change.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?
Get a detailed picture of the Rx/Reimbursement adult incontinence market;
Pinpoint growth sectors and identify factors driving change;
Understand the competitive environment, the market’s major players and leading brands;
Use five-year forecasts to assess how the market is predicted to develop.
Note: Product cover images may vary from those shown
2 of 4
RX/REIMBURSEMENT ADULT INCONTINENCE IN BELGIUM

May 2018

Headlines
Prospects
An Allocation Is Available
Reimbursement Will Increase in the Future

Category Data
Table 1 Sales of Rx/Reimbursement Adult Incontinence: Total Value MSP 2012-2017
Table 2 Sales of Rx/Reimbursement Adult Incontinence: Total Value MSP Growth 2012-2017
Table 3 Forecast Sales of Rx/Reimbursement Adult Incontinence: Total Value MSP 2017-2022
Table 4 Forecast Sales of Rx/Reimbursement Adult Incontinence: Total Value MSP Growth 2017-2022
Executive Summary
Overall Tissue and Hygiene Sales Are Stable
Premiumisation Is Evident in Retail Tissue
Private Label Is Big But Decreasing
Sales Are Generated Through Diverse Channels
A Decline in Value Sales Is Expected Over the Forecast Period
Market Indicators
Table 5 Birth Rates 2012-2017
Table 6 Infant Population 2012-2017
Table 7 Female Population by Age 2012-2017
Table 8 Total Population by Age 2012-2017
Table 9 Households 2012-2017
Table 10 Forecast Infant Population 2017-2022
Table 11 Forecast Female Population by Age 2017-2022
Table 12 Forecast Total Population by Age 2017-2022
Table 13 Forecast Households 2017-2022

Market Data
Table 14 Retail Sales of Tissue and Hygiene by Category: Value 2012-2017
Table 15 Retail Sales of Tissue and Hygiene by Category: % Value Growth 2012-2017
Table 16 NBO Company Shares of Retail Tissue and Hygiene: % Value 2013-2017
Table 17 LBN Brand Shares of Retail Tissue and Hygiene: % Value 2014-2017
Table 18 Penetration of Private Label in Retail Tissue and Hygiene by Category: % Value 2012-2017
Table 19 Distribution of Retail Tissue and Hygiene by Format: % Value 2012-2017
Table 20 Distribution of Retail Tissue and Hygiene by Format and Category: % Value 2017
Table 21 Forecast Retail Sales of Tissue and Hygiene by Category: Value 2017-2022
Table 22 Forecast Retail Sales of Tissue and Hygiene by Category: % Value Growth 2017-2022
Sources
Summary 1 Research Sources
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll